As an example, the KEYNOTE 001 study (n = 496), demonstrated a positive correlation between PD-L1 expression and treatment outcome in patients with advanced NSCLC treated with pembrolizumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.